Autoimmune disease with severe Muscle weakness in dogs (Myasthenia Gravis)
- Synonyms: Myasthenia gravis
- Occurrence: rarer
- Location of disease: General/Whole body
When to visit the vet?
Urgent see a veterinarian within 24 hours
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Myasthenia gravis is an autoimmune neuromuscular disease that leads to muscle weakness and fatigue in dogs. It occurs when the dog’s immune system mistakenly attacks its own acetylcholine receptors, which are crucial for transmitting impulses between nerves and muscles.
Das Wichtigste auf einen Blick
Myasthenia Gravis is a neuromuscular disease in dogs caused by disrupted communication between nerves and muscles. The immune system mistakenly attacks the receptors for the neurotransmitter acetylcholine, impairing the muscle response. Genetic factors play a role, with certain breeds like Akita and Jack Russell Terrier being more susceptible. Environmental factors such as stress or infections can also be triggers. Symptoms include Muscle weakness, Gait instability, and Respiratory distress. Diagnosis is made through clinical examinations, blood tests to determine antibodies, and imaging techniques. The Tensilon test can show temporary improvements in muscle strength.
Treatment aims to improve muscle strength and reduce the autoimmune reaction. Medications such as anticholinesterase inhibitors and immunosuppressants are used. In cases of megaesophagus, special feeding techniques are required. The prognosis depends on the severity of the disease; early diagnosis and treatment are crucial. There is no specific prevention, but stress reduction and infection avoidance can help. Research focuses on genetic factors, improved diagnostic procedures, and new therapy approaches, including regenerative medicine and nutrition.
Ursachen
The neuromuscular junction is vital for normal muscle contraction. This connection relies on the release of the neurotransmitter acetylcholine by nerve cells, which then binds to receptors on the muscle cell membrane and triggers a muscle contraction. In myasthenia gravis, this process is disrupted.
In a healthy body, there is a balance between the production of acetylcholine and the number of acetylcholine receptors. However, in dogs with myasthenia gravis, the immune system mistakenly attacks and destroys these receptors, impairing the muscle response. This autoimmune reaction can be triggered by genetic or environmental factors.
Although the exact cause is unknown, genetic predispositions are thought to play a role. Certain breeds such as Akitas, Jack Russell Terriers, and Great Danes seem to be more susceptible, indicating a genetic component. Furthermore, environmental factors such as infections or stress can act as triggers.
Symptoms
The symptoms of Myasthenia Gravis can vary, but the main feature is muscle weakness, which worsens after physical activity and improves after rest periods. This is often the first sign that dog owners notice.
Dogs may have difficulty walking, climbing stairs, or getting up. In severe cases, megaesophagus can occur, which is an enlargement of the esophagus that leads to swallowing difficulties and Vomiting. This can lead to life-threatening aspiration of food into the lungs.
Further symptoms can include facial muscle weakness, drooling, and a changed voice due to involvement of the throat. In some cases, weakness of the eyelids, known as ptosis, may also occur.
Diagnose
The diagnosis of Myasthenia Gravis requires a combination of clinical examination, blood tests, and imaging procedures. An important diagnostic test is the Tensilon test, in which a drug is administered that temporarily improves muscle strength if Myasthenia Gravis is present.
Another important test is the detection of antibodies against acetylcholine receptors in the blood. An elevated antibody level is a strong indicator of Myasthenia Gravis. Additionally, electromyography (EMG) and nerve conduction studies can be performed to evaluate the electrical activity of muscles and nerves.
Imaging techniques such as X-rays can help identify complications like megaesophagus. In some cases, a CT or MRI scan may also be required to rule out other neurological causes.
Therapie
Treatment for Myasthenia Gravis in dogs focuses on improving muscle strength and reducing the autoimmune reaction. Commonly used medications are anticholinesterase inhibitors such as pyridostigmine, which prolong the effect of acetylcholine and improve muscle contraction.
In severe cases, immunosuppressants such as prednisone may be required to suppress the autoimmune reaction. Careful monitoring and adjustment of the medication dosage are crucial to minimize side effects and ensure optimal treatment.
In dogs with megaesophagus, a special feeding technique is required to reduce the risk of aspiration. This may include feeding in an upright position or using special feeding bowls. In some cases, surgical treatment may be necessary.
Prognose und Nachsorge
The prognosis for dogs with Myasthenia Gravis varies depending on the severity of the disease and the response to treatment. Many dogs can lead a largely normal life with appropriate therapy, although regular veterinary check-ups are necessary.
Dogs with severe megaesophagus or other complications have a less favorable prognosis, as the risk of aspiration pneumonia and other life-threatening conditions is increased. Early diagnosis and treatment are crucial for a better prognosis.
Prävention
Since the exact causes of Myasthenia Gravis are not fully understood, there is no specific prevention. However, dog owners can minimize the risk of triggers by avoiding infections and reducing stress.
For breeds that are genetically predisposed, it is advisable to watch for early signs of the disease and seek veterinary attention early if suspected. Genetic counseling may be considered to minimize the risk in breeding.
Regular veterinary check-ups and timely treatment of symptoms can help improve the quality of life of dogs with Myasthenia Gravis and slow the progression of the disease.
Ausblick auf aktuelle Forschung
Current research on Myasthenia Gravis (MG) in dogs focuses on the genetic factors that contribute to the development of the disease. Scientists are investigating specific genes that could increase the risk of disease to better understand why some dogs are more likely to be affected than others. These genetic studies could enable targeted therapies in the future that are tailored to the genetic makeup of the individual dog.
Another area of research is the improvement of diagnostic procedures. Currently, MG is often diagnosed based on clinical symptoms and specific antibody-based blood tests. However, researchers are developing advanced imaging techniques and new biomarkers that could enable faster and more accurate diagnosis. These advances could shorten the waiting time for treatment and thus improve the prognosis for affected dogs.
Regarding therapy approaches, intensive research is being conducted into the development of new drugs that can specifically modulate the immune response. Current treatment options include immunosuppressants, which, however, often have side effects. New drugs that target the pathological mechanisms of MG more specifically could enable more effective and safer treatment.
Another exciting area of research is regenerative medicine. Scientists are investigating the possibility of regenerating muscle and nerve cells using stem cell therapies. These approaches could enable a long-term cure for MG by restoring the tissue damaged by the disease.
Finally, there are also studies dealing with the role of diet and lifestyle in managing MG. Researchers are investigating whether certain diets or dietary supplements can alleviate symptoms or slow the progression of the disease. These non-invasive approaches could represent a valuable supplement to existing treatments.
Frequently Asked Questions (FAQs)
1. What is Myasthenia Gravis in dogs?
2. What symptoms occur in dogs with Myasthenia Gravis?
3. Which breeds are particularly susceptible to Myasthenia Gravis?
4. How is Myasthenia Gravis diagnosed in dogs?
5. What treatment options are available for affected dogs?
6. Can Myasthenia Gravis be cured in dogs?
7. How does the disease affect a dog's daily life?
8. Can environmental factors influence Myasthenia Gravis?
9. Is Myasthenia Gravis in dogs contagious?
10. What is the prognosis for dogs with Myasthenia Gravis?
Literatur
- Dos Santos, R. X., Waelkens, J., Crawford, A. H., Khan, S., Sami, S., Gomes, S. A., Van Ham, A., Van Soens, I., Cornelis, I., Canning, J., Fenn, J., Waters, P., Bhatti, S. F. M., & Vanhaesebrouck, A. E. (2025). Case series of canine myasthenia gravis: A classification approach with consideration of seronegative dogs. Journal of Veterinary Internal Medicine, 39(3), Article e70113. https://doi.org/10.1111/jvim.70113
- Mignan, T., Targett, M., & Lowrie, M. (2020). Classification of myasthenia gravis and congenital myasthenic syndromes in dogs and cats. Journal of Veterinary Internal Medicine, 34(5), 1707–1717. https://doi.org/10.1111/jvim.15855
- Forgash, J. T., Chang, Y.-M., Mittelman, N. S., Petesch, S., Benedicenti, L., Galban, E., Hammond, J. J., Glass, E. N., Barker, J. R., Shelton, G. D., Luo, J., & Garden, O. A. (2021). Clinical features and outcome of acquired myasthenia gravis in 94 dogs. Journal of Veterinary Internal Medicine, 35(5), 2315–2326. https://doi.org/10.1111/jvim.16223
- Sänger, F., Ebner, F., Levitin, B., Eberspächer-Schweda, M. C., Tipold, A., & Fehr, M. (2023). Successful emergency management of a dog with ventilator-dependent fulminating myasthenia gravis using immunoadsorption. Animals, 14(1), Article 33. https://doi.org/10.3390/ani14010033
- Mignan, T., Lowrie, M., & Targett, M. (2023). Immune remission from generalized myasthenia gravis in a dog following thymectomy: A case report. Frontiers in Veterinary Science, 10, Article 1124702. https://doi.org/10.3389/fvets.2023.1124702
- Moffet, A. C. (2007). Metastatic thymoma and acquired generalized myasthenia gravis in a beagle. Canadian Veterinary Journal, 48(1), 91–93.
- Mondino, A., Fefer, G., Tauro, A., Olby, N., Lewis, M. J., & Mariani, C. L. (2025). Acquired myasthenia gravis in a juvenile Australian Shepherd dog and efficacy of leflunomide treatment. Case Reports in Veterinary Medicine, 2025, Article 1607891. https://doi.org/10.1155/crve/1607891